Evidence map›Paper›PMID 20194124›Full record

ReviewThe Journal of physiology2010

NaV1.1 channels and epilepsy.

William A Catterall, Franck Kalume, John C Oakley

Open access · greenAbstract readReview
In one paragraph

Review in The Journal of physiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 233 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
233citing papers in PubMed, 5 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

233 citing papers in PubMed, 5 syntheses or guidelines pooled it, 423 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Association BetweenFrontiers in neurology · 2020
    Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Augmenting and Assaying Nav1.1 Protein Quantity for Dravet Syndrome Therapy.Annals of clinical and translational neurology · 2026
    Article
  9. Prime editing of a pathogenicScience translational medicine · 2026
    Article
  10. Article
  11. Article
  12. CharacterizingmedRxiv : the preprint server for health sciences · 2026
    Article
  13. Article
  14. Article
  15. AFrontiers in genetics · 2026
    Article
  16. Review
  17. Observational
  18. Article
  19. Review
  20. Article

173 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

William A CatterallUniversity of Washington, Department of Pharmacology, SJ-30, Seattle, WA 98195-7280, USA. wcatt@u.washington.edu
Franck Kalume
John C Oakley
University of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Voltage-gated sodium channels initiate action potentials in brain neurons, and sodium channel blockers are used in therapy of epilepsy. Mutations in sodium channels are responsible for genetic epilepsy syndromes with a wide range of severity, and the NaV1.1 channel encoded by the SCN1A gene is the most frequent target of mutations. Complete loss-of-function mutations in NaV1.1 cause severe myoclonic epilepsy of infancy (SMEI or Dravet's Syndrome), which includes severe, intractable epilepsy and comorbidities of ataxia and cognitive impairment. Mice with loss-of-function mutations in NaV1.1 channels have severely impaired sodium currents and action potential firing in hippocampal GABAergic inhibitory neurons without detectable effect on the excitatory pyramidal neurons, which would cause hyperexcitability and contribute to seizures in SMEI. Similarly, the sodium currents and action potential firing are also impaired in the GABAergic Purkinje neurons of the cerebellum, which is likely to contribute to ataxia. The imbalance between excitatory and inhibitory transmission in these mice can be partially corrected by compensatory loss-of-function mutations of NaV1.6 channels, and thermally induced seizures in these mice can be prevented by drug combinations that enhance GABAergic neurotransmission. Generalized epilepsy with febrile seizures plus (GEFS+) is caused by missense mutations in NaV1.1 channels, which have variable biophysical effects on sodium channels expressed in non-neuronal cells, but may primarily cause loss of function when expressed in mice. Familial febrile seizures is caused by mild loss-of-function mutations in NaV1.1 channels; mutations in these channels are implicated in febrile seizures associated with vaccination; and impaired alternative splicing of the mRNA encoding these channels may also predispose some children to febrile seizures. We propose a unified loss-of-function hypothesis for the spectrum of epilepsy syndromes caused by genetic changes in NaV1.1 channels, in which mild impairment predisposes to febrile seizures, intermediate impairment leads to GEFS+ epilepsy, and severe or complete loss of function leads to the intractable seizures and comorbidities of SMEI.

Indexed as

AnimalsChannelopathiesChildEpilepsygamma-Aminobutyric AcidHumansIon Channel GatingMiceMutationMyoclonic Epilepsy, JuvenileNAV1.1 Voltage-Gated Sodium ChannelNerve Tissue ProteinsSeizures, FebrileSodium Channelsgamma-Aminobutyric AcidNAV1.1 Voltage-Gated Sodium ChannelNerve Tissue ProteinsSCN1A protein, humanScn1a protein, mouseSodium Channels

Identifiers

PMID20194124
PMCPMC2901973
OpenAlexW1564863670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.